[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-infected-individuals\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-infected-individuals":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100583750","phase-1-the-efficacy-and-safety-study-of-car-t-cells-for-functional-cure-in-hiv-1aids-patients-100583750",false,"NCT06880380","The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1\u002FAIDS Patients","HIV-CAR-T","Inclusion Criteria:\n\n1. Age between 18 and 65 years;\n2. Confirmed diagnosis of HIV-1 infection, with regular antiviral therapy ≥24 months prior to enrollment and sustained HIV-RNA levels \\\u003C50 copies\u002FmL for the 12 months preceding enrollment;\n3. CD4+ T-cell count \\>350\u002Fμl within 30 days prior to enrollment;\n4. Female participants of childbearing potential (including those ≤50 years old who are amenorrheic) must have a negative urine pregnancy test; from the screening period until the end of the study, participants should have no plans for conception and must voluntarily adopt effective contraceptive measures;\n5. Willingness to provide true identity information and comply with follow-up requirements;\n6. Ability to fully understand the study objectives, procedures, and potential risks, voluntary signing of an informed consent form, and adherence to the study requirements.\n\nExclusion Criteria:\n\n1. Women who are pregnant, breastfeeding, or of childbearing potential unwilling\u002Funable to use effective contraception.\n2. Coinfection with other viruses or infections, including HIV-2, HAV, HBV, HCV, HDV, HEV, EBV, CMV, or syphilis.\n3. History of AIDS-related opportunistic infections or malignancies within the past year (e.g., candidiasis, coccidioidomycosis, cryptococcosis, cytomegalovirus disease, herpes simplex, lymphoma).\n4. Autoimmune diseases requiring systemic immunosuppressive\u002Fimmunomodulatory therapy within the past 2 years (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus).\n5. Severe non-AIDS-related comorbidities, including uncontrolled clinically significant diseases of the genitourinary, cardiovascular, respiratory, neurological, psychiatric, gastrointestinal, endocrine, immune systems, or malignancies.\n6. Central nervous system (CNS) disorders, such as epilepsy, cerebral ischemia\u002Fhemorrhage, dementia, cerebellar diseases, or autoimmune conditions involving the CNS.\n7. Suspected or confirmed history of alcohol abuse, drug addiction, illicit substance use, or psychiatric disorders.\n8. Abnormal laboratory results within 14 days prior to enrollment meeting any of the following:\n\n   Hemoglobin \\\u003C10 g\u002FdL (female) or \\\u003C11 g\u002FdL (male) Absolute neutrophil count \\\u003C1 ×10⁹\u002FL Platelet count \\\u003C100 ×10⁹\u002FL Serum creatinine \\>110 μmol\u002FL INR \\>1.5 or PTT \\>45 seconds ALT or AST \\>2.5 × upper limit of normal (ULN) Total bilirubin \\>1.5 × ULN\n9. Current participation in another clinical trial that may conflict with the current protocol or outcome assessments.\n10. Any other condition deemed inappropriate for participation by the investigator.","ALL","18 Years","65 Years",{"count":5,"type":20},"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Autologous CAR-T cell therapy in HIV-1\u002FAIDS patients",[26,27],"HIV Infected Individuals","HIV",[29,27,30],"CAR-T","Autologous","RECRUITING","2026-03-03",{"date":34,"type":35},"2026-03-05","ACTUAL",{"date":37,"type":35},"2025-09-01",{"date":39,"type":20},"2026-07-01",{"name":41,"class":42},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100574703","phase-4-zoledronic-acid-for-the-prevention-of-tdf-sparing-art-induced-bone-mass-density-loss-in-treatment-naive-hiv-positive-individuals-100574703","NCT06762730","Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals","A Single Dose Intravenous Administration of Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals - a Prospective, Multicenter, Open-label, Randomized Control Trial","Inclusion Criteria:\n\n* Adults over age of 18 years old of any gender, social, religious or racial background.\n* Confirmed positive result for HIV infection.\n\nExclusion Criteria:\n\nPatients who received previous pharmacological agents for the prevention of HIV infection.\n\n* Women who are pregnant, lactating or those who plan to become pregnant within the trial timeframe.\n* Past history of severe drug-induced reaction (including atypical femur fractures or osteonecrosis of the jaw) or documented hypersensitivity to a bisphosphanate agent.\n* Patients with untreated hypocalcemia at screening.\n* Severe dental status",{"count":52,"type":20},110,[54],"PHASE4","The goal of this clinical trial is to learn if zolendric acid can prevent the anticipated deterioration of bone mass after antiviral treatment initiation for people that were recently diagnosed with HIV.\n\nThe main questions it aims to answer are:\n\n1. Is bone mass deterioration is significant even with the new medication currently used to treat HIV?\n2. Can one dose of Zolendric acid protect from deterioration of bone mass.\n\nResearchers will compare one dose of zolendric acid to follow-up only\n\nParticipant will:\n\n1. Provide blood samples for bone markers before antiviral treatment initiation and at 6M,12M,24M and 48M after treatment initiation\n2. Perform DXA scan soon after antiviral treatment initiation and after 12M ,24 M and 48 months\n3. Half of the patients with moderate reduction in bone mass will be treated with one dose of zolendric acid in the clinical trial, the other participants will be followed without intervention.\n4. Patients with substantial osteoporosis will be treated according to standard of care by their HMO, but will continue followup in the study.",[26,57],"Osteopenia",[57,59,60],"zoledronic acid","HIV naïve","2025-09-13",{"date":63,"type":35},"2025-09-18",{"date":65,"type":35},"2024-12-09",{"date":67,"type":20},"2032-12-01",{"name":69,"class":42},"Hadassah Medical Organization",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100497059","analysis-of-the-persistence-reservoir-and-hiv-latency-100497059","NCT05752318","Analysis of the Persistence, Reservoir and HIV Latency","APRIL Study: Analysis of the Persistence, Reservoir and HIV Latency","APRIL","Inclusion Criteria:\n\n* HIV-infection\n* Adults (\\>18 years)\n* Social insurance\n* Informed consent\n\nExclusion Criteria:\n\n* HIV-uninfected\n* \\\u003C18 years\n* Lack of social insurance\n* Lack or withdraw of consent",{"count":79,"type":20},500,"OBSERVATIONAL","The APRIL study aims at analyzing HIV reservoirs, latency and persistence on antiretroviral therapy. It enrolls HIV-infected adults providing blood samples of which peripheral blood mononuclear cells are stored. The frequency, phenotype and inducibility of HIV-infected cells are then analyzed. These parameters may vary across the different clinical and therapeutic settings.",[26,83],"Informed Consent",[27,85,86,87],"Reservoir","Latency","Persistence","NOT_YET_RECRUITING","2023-02-28",{"date":91,"type":35},"2023-03-02",{"date":93,"type":20},"2023-02-27",{"date":95,"type":20},"2027-02-25",{"name":97,"class":42},"University Hospital, Strasbourg, France"]